Drug intelligence / Profile preview

RD-2019-H076

Development stage: Preclinical
Lead developer: Apichope Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

RD-2019-H076 is an investigational small molecule drug candidate being developed by Apichope Pharmaceutical (also known as Yi Pin Hong Pharmaceutical) for the treatment of various respiratory system diseases. Currently in the preclinical stage of development, the agent is formulated as oral granules. As a Class 1 innovative drug in the developer's pipeline, it represents a novel chemical entity aimed at addressing therapeutic gaps in respiratory medicine. While the specific biological target and mechanism of action have not yet been publicly disclosed, the drug is part of a broader effort by Apichope to expand its portfolio in the respiratory therapeutic area.

Other names: RD-2019-H076 granulesRD2019-H076 granulesRD 2019-H076 granules

Beyond the preview

Go deeper on RD-2019-H076.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RD-2019-H076.

Explore the full profile